Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation (CGC) generates a steady flow of news as a cannabis-focused manufacturer with operations spanning medical and adult-use markets, branded products, and vaporization devices. The Canopy Growth news page on Stock Titan aggregates these disclosures so readers can follow how the company’s strategy, financing, and operations evolve over time.
Company news frequently covers financial performance and capital structure. Canopy Growth issues quarterly results releases that discuss cannabis and Storz & Bickel net revenue, segment performance in Canada and international markets, gross margins, operating loss, adjusted EBITDA, and free cash flow, along with commentary on cost management and balance sheet strength. The company also announces financing transactions, such as term loan agreements, prepayments on senior secured debt, convertible debenture exchanges, and at-the-market equity programs.
Another major category of news involves corporate transactions and governance. Canopy Growth has reported entering into an arrangement agreement to acquire MTL Cannabis Corp., detailing consideration, required approvals, and expected strategic benefits. It also publishes results of its annual general and special meetings, including director elections, auditor appointments, share consolidation authority, and advisory votes on executive compensation, as well as updates on board and executive appointments.
Product and market updates are a recurring theme. The company announces launches such as Claybourne Gassers liquid diamonds All-in-One vapes and Claybourne Frosted Flyers infused pre-roll variety packs in Canada, along with expansions of the Spectrum Therapeutics medical portfolio in Australia through new softgel formats. It also highlights operational moves like dedicating the DOJA facility in Kelowna to medical cultivation for Spectrum Therapeutics patients.
Investors and observers who monitor CGC news can use this page to track developments in Canopy Growth’s Canadian adult-use and medical businesses, its international medical operations in Europe and Australia, its indirect exposure to the U.S. THC market through Canopy USA, and its ongoing efforts to manage debt, liquidity, and governance matters. Bookmark this feed to review new press releases, transaction updates, and regulatory communications as they are published.
Martha Stewart CBD has expanded its product lineup with the launch of Tropical Medley CBD Wellness Gummies, featuring new flavors: Alphonso Mango, Coconut, and Pineapple. The gummies, made with 100% hemp-derived CBD isolate, aim to enhance consumer wellness experiences. Available in three sizes, prices range from $3.99 to $34.99, with online sales starting March 14, 2022. This launch reflects Canopy Growth's commitment to delivering high-quality CBD products and supports Martha Stewart's partnership with the company, enhancing brand visibility and market reach.
Canopy Growth Corporation (NASDAQ: CGC) announced its participation as Silver Sponsor at Natural Products Expo West 2022, taking place from March 8-12 in Anaheim, CA. The company will showcase its CBD brands, including Martha Stewart CBD and Quatreau, highlighting innovations in CBD wellness products. An industry panel, "Cannabis Evolution: The Latest Innovations and Trends in CBD and Wellness," will occur on March 10, featuring notable speakers from Canopy Growth and the CBD industry. The event aims to address consumer wellness needs through diverse CBD offerings.
Canopy Growth Corporation (CGC) reported its Q3 fiscal 2022 results, showing a 7% sequential revenue growth but an 8% decline year-over-year to $141 million. The cannabis revenue decreased by 20% while other consumer products, particularly BioSteel, saw a 130% increase in revenue. The company is focusing on reducing operating expenses, targeting profitability in Canada, and expanding its U.S. CBD and THC strategies. Despite a net loss of $115 million, it maintained a strong cash position of $1.4 billion. Actions are underway to enhance execution in the Canadian market.
Canopy Growth Corporation (NASDAQ: CGC) will announce its financial results for Q3 FY 2022 on February 9, 2022. The results will cover the period ending December 31, 2021, and a live audio webcast will follow at 10:00 AM ET the same day, featuring CEO David Klein and Interim CFO Judy Hong. Stakeholders can access a replay of the webcast until May 10, 2022. The company continues to expand its diverse cannabis and cannabinoid products, focusing on quality and customer relationships across various markets.
Martha Stewart CBD has launched a new line of CBD Wellness Topicals, marking its first category expansion. The product range includes Super Strength CBD Cream for muscle recovery, Sleep Science CBD Cream for sleep enhancement, and Daily De-Stress CBD Cream for stress management. Each cream is formulated with high CBD levels and innovative aroma-technology. The products are available in various sizes and competitively priced, with the goal of making wellness accessible and effective. This expansion is a collaborative effort with Canopy Growth Corporation.
Canopy Growth Corporation (NASDAQ: CGC) released its inaugural Environmental, Social, and Governance (ESG) Report for 2020, highlighting its commitment to sustainable practices. The report includes a baseline assessment of energy use and greenhouse gas emissions, a $1 million investment in drug war impact initiatives, and the registration of 23,000 patients in its Compassionate Pricing Program. Canopy Growth has taken significant steps towards diversity and inclusion, achieving near gender parity and establishing Employee Resource Groups. The company aims to lead the cannabis industry responsibly and sustainably.
Canopy Growth Corporation has agreed to divest its subsidiary, C³ Cannabinoid Compound Company GmbH, to Dermapharm Holding SE for an upfront payment of EUR80M (approx. CAD$115.5M) and potential earnout payments up to EUR42.6M (approx. CAD$61.4M). This strategic sale allows Canopy Growth to focus on its core consumer packaged goods model, reducing operational complexities and capital investment requirements by over CAD$50M. The transaction is expected to close by January 31, 2022, with all C³ employees remaining with Dermapharm.
Beatrice Society has announced the formation of its Board of Directors, appointing Gary Yeoman as Chairman. The board includes seasoned professionals Lorne Gertner and Krisztián Tóth. Yeoman, previously at Voxtur Analytics and Altus Group, aims to build on recent acquisitions in psychedelics and wellness. Gertner co-founded Cannasat Therapeutics and has notable ties to the cannabis industry, while Tóth specializes in corporate finance. The board's expertise is expected to strengthen Beatrice's position in the growing psychedelic therapy market.
On November 19, 2021, Canopy Growth announced critical changes in its Executive Management Committee. Mike Lee, Chief Financial Officer, and Rade Kovacevic, Chief Product Officer, will depart by December 31, 2021. Judy Hong and Tara Rozalowsky have been appointed as interim CFO and Chief Product Officer, respectively. CEO David Klein emphasized that these changes aim to enhance the company’s long-term growth and shareholder value. Canopy Growth continues to pursue its strategic priorities while maintaining its leadership position in the cannabis industry.
Canopy Growth Corporation (CGC) reported financial results for Q2 FY2022, ending September 30, 2021. Net revenue was $131.4 million, a 3% decline from Q2 FY2021, with cannabis revenue rising 1% to $95 million. The company announced plans to acquire Wana Brands, enhancing its U.S. presence. Gross margin dropped to -54%, impacted by inventory write-downs of $87 million, while adjusted EBITDA loss widened to $163 million. Despite challenges, Canopy remains optimistic about U.S. growth, aiming to stabilize Canadian operations and enhance product distribution.